Patents by Inventor Andrew D. J. Goodearl

Andrew D. J. Goodearl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using transporter-like molecules to treat pain and pain-related disorders
    Publication number: 20030159162
    Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.
    Type: Application
    Filed: March 11, 2003
    Publication date: August 21, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew D. J. Goodearl, Inmaculada Silos-Santiago
  • Methods of using transporter-like molecules to treat pain and pain-related disorders
    Patent number: 6573057
    Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: June 3, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew D. J. Goodearl, Inmaculada Silos-Santiago
  • TRANSGENIC GPCR EXPRESSING ANIMALS
    Publication number: 20020166131
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 (“mACHR-6”) nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 8, 1999
    Publication date: November 7, 2002
    Applicant: Millennium Pharmaceuticals, Inc
    Inventors: ANDREW D. J. GOODEARL, M. ALEXANDRA GLUCKSMANN
  • Tango 71 nucleic acids
    Patent number: 6416974
    Abstract: The invention relates to Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83 polypeptides, nucleic acid molecules encoding Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, and uses thereof.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: July 9, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, Andrew D. J. Goodearl
  • Methods for detecting nucleic acid molecules encoding a member of the muscarinic family of receptors
    Patent number: 6093545
    Abstract: The invention provides methods for detecting the presence of a nucleic molecule encoding a muscarinic acetylcholine receptor 6 ("mACHR-6") family member.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: July 25, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew D. J. Goodearl, M. Alexandra Glucksmann
  • Schwann cell mitogenic factor, its preparation and use
    Patent number: 5594114
    Abstract: The invention provides a new Schwann cell-mitogenic factor of molecular weight about 43 to 45 kilodaltons, when isolated by SDS-PAGE. The invention provides therapeutic formulation comprising the new factor, and the use of the factor and the said formulations in treating conditions which involve a factor-sensitive or factor-responsive cell type.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: January 14, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Andrew D. J. Goodearl, Paul Stroobant, Michael D. Waterfield